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Recent phase III trials have confirmed that 1p/19q codeletion in 
anaplastic oligodendrogliomas and oligoastrocytomas is sig-
nificantly associated with increased chemosensitivity to alkylat-
ing agents, and this translates into improved outcome.1,2 Given 
the potential longer survival of these patients compared with 
high-grade astrocytoma patients, a treatment approach of initial 
chemotherapy with dose-intensification strategies and delayed 
radiation therapy (RT) at tumor progression to prevent the risk 
of cognitive defects could be attractive. In this regard, high-dose 
myeloablative chemotherapy followed by autologous stem cell 
transplant is an approach whose main objective is to achieve 
higher CNS drug concentrations to maximize the chemorespon-
siveness with an acceptable degree of systemic and neurologic 
toxicity.
In this issue of Neuro-Oncology, Thomas and colleagues3 
report the results of a multicenter phase II study of temozolo-
mide (TMZ) and myeloablative chemotherapy with autologous 
stem cell transplant in a cohort of newly diagnosed anaplastic 
oligodendrogliomas and oligoastrocytomas whose diagnosis 
was based on the World Health Organization (WHO) 2000 classi-
fication. Induction chemotherapy consisted of 6 cycles of stand-
ard TMZ. Patients achieving a response or stable disease of the 
enhancing tumor on MRI were eligible for high-dose thiotepa 
and busulfan with autologous stem cell support. Forty-one 
patients were enrolled over a 7-year period. By the end of induc-
tion chemotherapy, 9 patients experienced disease progression, 
and another 11 withdrew for several reasons, so that 21 patients 
only were transplanted. Twenty of these patients had 1p/19q 
codeletion and in 1 patient 1p/19q status was unknown.
The first question that now arises is whether high-dose 
chemotherapy using TMZ in the induction phase is superior to 
standard treatment or dose dense TMZ as an upfront treatment 
in 1p/19q codeleted patients; however, available data for com-
parison are scarce and do not allow definitive conclusions. In 
fact, in the study by Thomas et al,3 the transplanted patients (n 
= 21) had a 5-year progression-free survival (PFS) of 60.4% and 
a 5-year overall survival (OS) of 100% (with a median follow-
up of 65.7 months), while in the recent multicenter single arm 
phase II trial of Ahluwalia and colleagues4 using dose dense 
TMZ (1 wk on/1 wk off) in 20 patients, 5-year PFS was 55% and 
5-year OS was ~90%. 
A second, more general question is whether upfront chem-
otherapy with RT delayed until tumor progression in 1p/19q 
codeleted patients can yield similar survival results compared 
with an early combination of radiation and chemotherapy. The 
2 phase III trials1,2 that reported a significant superiority of RT 
followed by procarbazine/lomustine/vincristine (PCV) over 
RT alone in terms of PFS and OS have established the bench-
mark for future comparisons. In particular, in the European 
Organisation for Research and Treatment of Cancer (EORTC) 
trial,2 1p/19q codeleted patients who received RT + PCV (n = 43) 
had a 5-year PFS of 71.4% and a 5-year OS of 76.2% The long-
term results of NOA-04 suggest that chemotherapy alone may 
have a worse outcome,5 while a large retrospective analysis6 
showed no difference in the median OS of patients with 1p/19q 
codeleted anaplastic oligodendrogliomas who had initially 
received chemotherapy alone (median 10.5 y) versus those 
receiving chemoradiotherapy (median 8.4 y).
Overall, some issues are critical in this debate. It is unknown 
whether salvage RT is as efficacious as early RT, and even 
more important, it is unknown whether a potential shorter sur-
vival following upfront chemotherapy alone compared with RT 
followed by chemotherapy is balanced by a better preserva-
tion of cognitive functions and quality of life.
Data are lacking, but a small retrospective study on long-
term survivors of anaplastic oligodendroglioma in the EORTC 
study, receiving either RT alone or associated with PCV, has 
suggested that a substantial proportion of patients suffered 
from cognitive impairment while being health-related quality 
of life stable.7 Future studies need to incorporate serial moni-
toring of cognitive functions over many years of follow-up to 
better clarify this issue, and this is not an easy task.
There are still conflicting data regarding a possible dif-
ferential efficacy of PCV and TMZ. Both the retrospective 
study by Lassman et al6 in 1p/19q codeleted patients and 
the study by Wick et al5 of the NOA-04 study of cytosine-
phosphate-guanine island methylated phenotype codeleted 
patients have reported a superior efficacy of PCV over TMZ. 
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The current phase III CODEL trial is being conducted 
under the assumption that chemoradiotherapy using 
TMZ or PCV will have similar efficacy with a better toler-
ability profile favoring TMZ: This has been recently sug-
gested by a large retrospective study by Speirs et al.8 
Interestingly, two studies comparing TMZ versus PCV 
as induction regimen before higher-dose chemotherapy 
with autologous stem cell transplantation3,9 have shown 
that patients enrolled in the PCV cohort had shorter 
median OS than those enrolled on TMZ.
In conclusion, it remains to be demonstrated whether 
a proportion of patients with anaplastic oligodendroglio-
mas, who according to the WHO 2016 Classification10 have 
by definition 1p/19q codeletion, derive additional survival 
benefit from a transplantation procedure compared with 
some standard options. Future studies should better define 
the characteristics of those patients who are candidates for 
this aggressive procedure, patterns of response to salvage 
treatments, and last but not least, cognitive status and 
quality of life.
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